A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

Trial Profile

A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Daratumumab (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms MAIA
  • Sponsors Genmab; Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 15 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 29 Jun 2017 Planned End Date changed from 22 Nov 2022 to 22 Nov 2024.
    • 22 Apr 2015 New source identified and integrated (European Clinical Trials database record : EudraCT2014-002273-11).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top